Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - donepezil hydrochloride, quantity: 10 mg (equivalent: donepezil, qty 9.12 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; maize starch; lactose monohydrate; hyprolose; titanium dioxide; macrogol 8000; hypromellose; purified talc; iron oxide yellow - aricept (donepezil hydrochloride) is indicated for the treatment of mild, moderate and severe alzheimer's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - donepezil hydrochloride, quantity: 5 mg (equivalent: donepezil, qty 4.56 mg) - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; hyprolose; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 8000; purified talc - aricept (donepezil hydrochloride) is indicated for the treatment of mild, moderate and severe alzheimer's disease.

United States - English - NLM (National Library of Medicine)

eisai inc. - donepezil hydrochloride (unii: 3o2t2pj89d) (donepezil - unii:8ssc91326p) - solution - 1 mg in 1 ml - aricept® is indicated for the treatment of dementia of the alzheimer's type. efficacy has been demonstrated in patients with mild to moderate alzheimer's disease, as well as in patients with severe alzheimer's disease. aricept® is contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - donepezil hydrochloride (unii: 3o2t2pj89d) (donepezil - unii:8ssc91326p) - donepezil hydrochloride 5 mg - aricept is indicated for the treatment of dementia of the alzheimer's type. efficacy has been demonstrated in patients with mild, moderate, and severe alzheimer's disease. aricept is contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives. pregnancy category c: there are no adequate or well-controlled studies in pregnant women. aricept should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral administration of donepezil to pregnant rats and rabbits during the period of organogenesis did not produce any teratogenic effects at doses up to 16 mg/kg/day (approximately 6 times the maximum recommended human dose [mrhd] of 23 mg/day on a mg/m2 basis) and 10 mg/kg/day (approximately 7 times the mrhd on a mg/m2 basis), respectively. oral administration of donepezil (1, 3, 10 mg/kg/day) to rats during late gestation and throughout lactation to weaning produced an increase in stillbirths and reduced offspring s

United States - English - NLM (National Library of Medicine)

eisai inc. - donepezil hydrochloride (unii: 3o2t2pj89d) (donepezil - unii:8ssc91326p) - donepezil hydrochloride 5 mg - aricept is indicated for the treatment of dementia of the alzheimer’s type. efficacy has been demonstrated in patients with mild, moderate, and severe alzheimer’s disease. aricept is contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives. risk summary there are no adequate data on the developmental risks associated with the use of aricept  in pregnant women. in animal studies, developmental toxicity was not observed when donepezil was administered to pregnant rats and rabbits during organogenesis, but administration to rats during the latter part of pregnancy and throughout lactation resulted in increased stillbirths and decreased offspring survival at clinically relevant doses [see data ]. in the u.s. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively. the background risks of major birth defects and miscarriage for the indicated popula

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - donepezil hydrochloride (unii: 3o2t2pj89d) (donepezil - unii:8ssc91326p) - donepezil hydrochloride 10 mg - aricept is indicated for the treatment of dementia of the alzheimer’s type. efficacy has been demonstrated in patients with mild, moderate, and severe alzheimer’s disease. aricept is contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives. risk summary there are no adequate data on the developmental risks associated with the use of aricept  in pregnant women. in animal studies, developmental toxicity was not observed when donepezil was administered to pregnant rats and rabbits during organogenesis, but administration to rats during the latter part of pregnancy and throughout lactation resulted in increased stillbirths and decreased offspring survival at clinically relevant doses [ see data ]. in the u.s. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively. the background risks of major birth defects and miscarriage for the i

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - donepezil hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - donepezil hydrochloride -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eisai ltd - donepezil hydrochloride - oral tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eisai ltd - donepezil hydrochloride - oral tablet - 10mg